Arrayit to Bring First Pre-Symptomatic Ovarian Cancer Test to Market in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation, Thursday formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development — the rights to which have been assigned exclusively to the Company by Arrayit Corporation.
Yahoo!